Elevai Biosciences

Elevai Biosciences, a subsidiary of Elevai Labs, is a biotechnology company specializing in the development of exosome-based applications for medical aesthetics and systemic health. The company utilizes its proprietary PREG-EX platform, which leverages human umbilical mesenchymal stem cell-derived exosomes to promote skin rejuvenation and tissue repair. Their lead therapeutic candidate, EL-22, is an engineered exosome-based therapy targeting myostatin for the treatment of obesity and muscle loss, specifically designed to preserve muscle mass in patients using GLP-1 receptor agonists. Elevai also markets a commercial line of physician-dispensed aesthetic products, including the E-Series, which are used post-procedure to enhance skin recovery. The company is focused on integrating regenerative medicine with aesthetic dermatology to provide next-generation cellular signaling treatments.